<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03749642</url>
  </required_header>
  <id_info>
    <org_study_id>039(1)PO16357</org_study_id>
    <secondary_id>2018-000133-12</secondary_id>
    <nct_id>NCT03749642</nct_id>
  </id_info>
  <brief_title>Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy</brief_title>
  <official_title>Efficacy and Safety of Fixed-Dose Combination (FDC) Products Containing Trazodone and Gabapentin in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose Finding Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to collect preliminary information on the effect of&#xD;
      three doses of trazodone/gabapentin FDC products on pain intensity in patients with painful&#xD;
      diabetic neuropathy after 8-week treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present phase II study is designed to collect preliminary data on the efficacy and safety&#xD;
      of trazodone/gabapentin Fixed-Dose Combination (FDC)products for treatment of patients&#xD;
      affected by painful diabetic neuropathy in a randomized controlled clinical trial. Diabetic&#xD;
      peripheral neuropathic pain represents an important therapeutic challenge as its&#xD;
      pathophysiology is not yet fully understood and pain relief is still unsatisfactory. The&#xD;
      pharmacological treatments, with exception to those targeted to the glycemic control, are&#xD;
      symptomatic and their use is limited by not universal efficacy, side effects or by the&#xD;
      development of tolerance. A wide variety of drugs, used both alone and in combination, has&#xD;
      shown to significantly reduce neuropathic pain when compared with placebo in randomized&#xD;
      controlled trials, even though pain relief remains inadequate for most of the patients.&#xD;
&#xD;
      In this contest, Angelini S.p.A is developing a fixed-dose combination medicinal product for&#xD;
      the treatment of neuropathic pain containing low doses of active ingredients: trazodone, a&#xD;
      widely used antidepressant drug, and gabapentin which is indicated for the treatment of&#xD;
      neuropathic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2018</start_date>
  <completion_date type="Actual">June 6, 2020</completion_date>
  <primary_completion_date type="Actual">June 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo and reference controlled, placebo unbalanced, double-dummy, dose finding, parallel group, multicentre, international, prospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The present study will be performed in double blind conditions. During the study neither the Investigator nor the patient will be aware of the treatment assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).</measure>
    <time_frame>Baseline - Day 56</time_frame>
    <description>The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 42</time_frame>
    <description>The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responder patients</measure>
    <time_frame>Baseline - Day 56</time_frame>
    <description>Responder patients are defined as ≥30% and ≥50% reduction from baseline of the average daily pain score based on the 11-point NRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the average daily pain score based on the 11-point NRS between gabapentin and placebo as assay sensitivity.</measure>
    <time_frame>Baseline - Day 56</time_frame>
    <description>The NRS is based on a 11-point from 0 for [no pain] to 10 [worst possible pain].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Brief Pain Inventory Short Form (BPI-SF) items 3, 4, 5, 6, 8 and 9 score.</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The BPI-SF is a numeric rating scale that assesses the severity of pain, its impact on daily functioning and other aspects of pain (e.g. location of pain, relief from medications). Items use a 0-10 numeric rating scale anchored at zero for &quot;no pain&quot; and 10 for &quot;pain as bad as you can imagine&quot; for Severity, and &quot;does not interfere&quot; to &quot;completely interferes&quot; for Interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Neuropathic Pain Symptom Inventory (NPSI) total score.</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The NPSI is a self-questionnaire specifically designed to evaluate the different symptoms of neuropathic pain: It includes 10 descriptors plus two temporal items that allow discrimination and quantification of five distinct clinically relevant dimensions of neuropathic pain syndromes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Beck Depression Inventory - Second Edition (BDI-II)</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The BDI-II consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression and scored from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hospital Anxiety and Depression Scale (HADS).</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The HADS is used to assess the level of anxiety and depression that a patient is experiencing. This is 14-item scale: seven related to the anxiety and seven to depression. Each item is scored from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Insomnia Severity Index (ISI).</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The ISI is a 7-item self-reported instrument measuring the patient's perception of his/her insomnia.Total score ranges from 0-28 and the following categorization is applicable: 0-7 = absence of insomnia; 8-14 = subthreshold insomnia; 15-21 = moderate insomnia; 22-28 = severe insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Euroqol-5D-5L (EQ-5D-5L)</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>The EQ-5D-5L consists of the EQ-5D descriptive system (five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression assessed as no problems, slight problems, moderate problems, severe problems and extreme problems) and the EQ visual analogue scale (where the patient self-rates his/her health on a vertical visual analogue scale from 'The best health you can imagine' to 'The worst health you can imagine').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Improvement or Change (CGI-C).</measure>
    <time_frame>Baseline - Days 28, 56</time_frame>
    <description>CGI-C provides a global rating of patient's Improvement and scores range from &quot;0 - not assessed&quot; through to &quot;7 - very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>65 days</time_frame>
    <description>Monitoring of the treatment related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>trazodone/gabapentin 2.5/25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trazodone/gabapentin 5/50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule, three times a day, for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trazodone/gabapentin 10/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule, three times a day, for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules, three times a day, for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>according to the following scheduling dosage regimen:&#xD;
100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);&#xD;
300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);&#xD;
400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);&#xD;
300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trazodone/gabapentin 2.5/25 mg</intervention_name>
    <description>The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.</description>
    <arm_group_label>trazodone/gabapentin 2.5/25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trazodone/gabapentin 5/50 mg</intervention_name>
    <description>The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.</description>
    <arm_group_label>trazodone/gabapentin 5/50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trazodone/gabapentin 10/100</intervention_name>
    <description>The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.</description>
    <arm_group_label>trazodone/gabapentin 10/100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>The total daily doses administered will be:&#xD;
600 mg from day 0 to day 6 (±1)&#xD;
900 mg from day 7 (±1) to day 13 (±1)&#xD;
1200 mg from day 14 (±1) to day 20 (±1)&#xD;
1800 mg from day 21 (±1) to day 56 (±2)</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Two capsules, three times a day, for 8 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patient of any ethnic origin between 18 and 75 years of age (limits&#xD;
             included).&#xD;
&#xD;
          2. Neuropathic pain at feet/legs confirmed by Douleur Neuropatique 4 (DN4) score ≥ 4 at&#xD;
             Screening Visit.&#xD;
&#xD;
          3. Patient with bilateral distal symmetrical polyneuropathy confirmed by Toronto Clinical&#xD;
             Neuropathy Scoring System (TCNSS) score &gt; 5 at Screening visit.&#xD;
&#xD;
          4. Pain persisting or taking pain medication for neuropathic pain for at least 3 months.&#xD;
&#xD;
          5. Diabetic patient (type 1 or 2 diabetes mellitus) with value of glycated haemoglobin ≤&#xD;
             11% at Screening Visit and stable antidiabetic medication regimen for ≥30 days.&#xD;
&#xD;
          6. Patient who is currently not receiving treatment for diabetic neuropathic pain or&#xD;
             patient who is receiving treatment, with drug/s other than gabapentin, and has&#xD;
             completed the required washout.&#xD;
&#xD;
          7. Average daily pain score ≥ 4 based on the 11-point Numeric Rating Scale (NRS) at Visit&#xD;
             0, calculated from a minimum of four pain ratings in daily electronic device entries&#xD;
             during the baseline period.&#xD;
&#xD;
          8. Women of childbearing potential must have a negative pregnancy test at Screening Visit&#xD;
             and have to agree not to start a pregnancy from the signature of the informed consent&#xD;
             up to thirty days after the last administration of the investigational product, using&#xD;
             an appropriate birth control method, such as combined estrogen and progestogen&#xD;
             containing hormonal contraception (e.g. oral, intravaginal, transdermal),&#xD;
             progestogen-only hormonal contraception (e.g. oral, injectable, implantable),&#xD;
             intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) in&#xD;
             combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual&#xD;
             abstinence.&#xD;
&#xD;
          9. Legally capable to give their consent to participate in the study (including personal&#xD;
             data processing) and available to sign and date the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to trazodone or gabapentin or any excipients of the test drugs.&#xD;
&#xD;
          2. Any other form of non-diabetic distal symmetric polyneuropathy or any other pain&#xD;
             condition that can impair the study endpoint (e.g. painful conditions where the&#xD;
             intensity of pain is significantly more severe than the diabetic peripheral&#xD;
             neuropathic pain).&#xD;
&#xD;
          3. Concomitant treatment with medications for pain management that could not be&#xD;
             discontinued.&#xD;
&#xD;
          4. Concomitant treatment with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir,&#xD;
             indinavir) or drugs known to prolong QT interval.&#xD;
&#xD;
          5. Use of trazodone or gabapentin in the previous 3 months.&#xD;
&#xD;
          6. Known history of previous non-responder to gabapentin treatment.&#xD;
&#xD;
          7. Use of high dose morphine (e.g. &gt; 120 mg/day) at the Screening Visit.&#xD;
&#xD;
          8. Clinically significant abnormalities on physical examination, vital signs,&#xD;
             elettrocardiogram, laboratory tests at Screening Visit that in the opinion of&#xD;
             Investigator would compromise patient's participation in the study.&#xD;
&#xD;
          9. Active foot ulcer or previous major limb amputation.&#xD;
&#xD;
         10. Concurrent heart failure ≥ 4 class according to New York Heart Association (NYHA) or&#xD;
             myocardial infarction or angioplasty or by-pass graft procedures within the past 6&#xD;
             months.&#xD;
&#xD;
         11. Patient with increased risk of Torsade de Pointes (e.g. family history of long QT&#xD;
             syndrome) or QTcF value higher than 450 msec (male) and QTcF value higher than 470&#xD;
             msec (female) at Screening Visit.&#xD;
&#xD;
         12. Transient ischemic attack or cerebral vascular accident within the past 6 months.&#xD;
&#xD;
         13. Glomerular Filtration Rate value &lt; 50 ml/min calculated with Modification of Diet in&#xD;
             Renal Disease formula.&#xD;
&#xD;
         14. Significant liver disease, defined as known active hepatitis or elevated liver enzymes&#xD;
             over 3-fold the upper normal limit of laboratory normal ranges.&#xD;
&#xD;
         15. Patient with latent or known hereditary problems of galactose intolerance or the Lapp&#xD;
             lactase deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
         16. Positive urine drug screen for Central Nervous System active drugs (cocaine, opioids,&#xD;
             amphetamines and cannabinoids) at Screening Visit.&#xD;
&#xD;
         17. Positive present history of glaucoma.&#xD;
&#xD;
         18. Hyperthyroidism, even if pharmacologically corrected.&#xD;
&#xD;
         19. Significant mental disorders.&#xD;
&#xD;
         20. Suicide risk score ≥ 2 on question 9 of the Beck Depression Inventory-II (BDI-II) at&#xD;
             Screening visit or Visit 0.&#xD;
&#xD;
         21. History of epilepsy or seizure events other than a single childhood febrile seizure.&#xD;
&#xD;
         22. History of alcohol or psychoactive substance abuse or addiction.&#xD;
&#xD;
         23. Use of neurological device (e.g. neurostimulation devices, etc).&#xD;
&#xD;
         24. Women during pregnancy or lactation period.&#xD;
&#xD;
         25. Inability to comply with the protocol requirements, instructions or study-related&#xD;
             restrictions (e.g. uncooperative attitude, inability to return for study visits,&#xD;
             improbability of completing the clinical study, etc).&#xD;
&#xD;
         26. Subject involved in the conduct of the study (e.g. Investigator or his/her deputy,&#xD;
             first grade relatives, pharmacist, assistant or other personnel, etc).&#xD;
&#xD;
         27. Participation to an interventional clinical trial within 3 months prior to Screening&#xD;
             Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solomon Tesfaye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Teaching Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurosanatio s.r.o.</name>
      <address>
        <city>Litomyšl, 570 01</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cerebrovaskulární poradna, s.r.o.</name>
      <address>
        <city>Ostrava - Poruba, 70800</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubického kraje a.s. Pardubická nemocnice Neurologická klinika</name>
      <address>
        <city>Pardubice, 532 03</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologická ambulance Milan Kvapil s.r.o.</name>
      <address>
        <city>Praha 4, 149 00</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axon Clinical s.r.o</name>
      <address>
        <city>Praha 5, 15000</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FORBELI s.r.o.</name>
      <address>
        <city>Praha 6, 160 00</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial s.r.o.</name>
      <address>
        <city>Praha, 100 00</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Hôtel Dieu Groupe SOS Service de Diabétologie</name>
      <address>
        <city>Le Creusot, 71200</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHR MSA - Hôpital Emile Muller Service de Diabétologie-Endocrinologie-Nutrition</name>
      <address>
        <city>Mulhouse, 68100</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital Guillaume-et-René-Laënnec Clinique d'Endocrinologie, maladies métaboliques et nutrition CIC Endocrino - Nutrition - UF 7015</name>
      <address>
        <city>Nantes Cedex 144 093</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Clinique G.H.M les Portes du Sud Departement d'Endocrinologie</name>
      <address>
        <city>Venissieux, 69200</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House</name>
      <address>
        <city>Gdansk, 80-546</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silmedic Sp. z o.o.</name>
      <address>
        <city>Katowice, 40-282</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro Familia Altera Poradnia Wielospecjalistyczna</name>
      <address>
        <city>Katowice, 40-648</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET</name>
      <address>
        <city>Kraków, 31-261</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Neuromed M. i M. Nastaj Sp. P.</name>
      <address>
        <city>Lublin, 20-064</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medycyny Wsi im. Witolda Chodźki Klinika Diabetologii</name>
      <address>
        <city>Lublin, 20-090</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne HCP Sp. z o.o.</name>
      <address>
        <city>Poznań, 61-485</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddział Sochaczew</name>
      <address>
        <city>Sochaczew, 96-500</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń, 87-100</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa, 00-874</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Diabetologii</name>
      <address>
        <city>Warszawa, 04-736</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica I. Bielicka, A. Strzałkowska s.c.</name>
      <address>
        <city>Wrocław, 51- 685</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych Ośrodek Badań Wczesnej Fazy</name>
      <address>
        <city>Wrocław, 51-162</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Innovation Development and Research Unit (MIDRU) Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Centre Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Clinical Research Facility Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Centre George Eliot Hospital NHS Trust</name>
      <address>
        <city>Nuneaton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancashire Clinical Research Facility The Avondale Unit Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trazodone</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Neuropathic pain</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

